End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
0.23 SEK | +9.52% |
|
-17.86% | -34.29% |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 32.3 | 42.4 | 47.29 | 52.78 | 24.08 | 20.02 |
Enterprise Value (EV) 1 | 23.34 | 39.89 | 41.74 | 51.82 | 26.03 | 24.38 |
P/E ratio | -3.42 x | -5.27 x | -6.73 x | -13.7 x | -4.13 x | -3.25 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | 4.18 x | 7.4 x | 6.02 x | 6.39 x | 2.93 x | 3.3 x |
EV / Revenue | 3.02 x | 6.96 x | 5.31 x | 6.28 x | 3.17 x | 4.02 x |
EV / EBITDA | -2.53 x | -5.12 x | -7.18 x | -15.2 x | -4.9 x | -4.36 x |
EV / FCF | 2.04 x | -9.86 x | -7.38 x | -16.6 x | -4.16 x | -9.55 x |
FCF Yield | 49% | -10.1% | -13.5% | -6.03% | -24% | -10.5% |
Price to Book | 2.49 x | 7.67 x | 4.91 x | 9.16 x | 4.43 x | 11.3 x |
Nbr of stocks (in thousands) | 45,493 | 46,188 | 50,038 | 57,188 | 57,188 | 57,188 |
Reference price 2 | 0.7100 | 0.9180 | 0.9450 | 0.9230 | 0.4210 | 0.3500 |
Announcement Date | 4/29/19 | 4/23/20 | 4/20/21 | 5/4/22 | 5/10/23 | 6/5/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales 1 | 7.729 | 5.733 | 7.861 | 8.259 | 8.221 | 6.064 |
EBITDA 1 | -9.211 | -7.788 | -5.809 | -3.405 | -5.313 | -5.591 |
EBIT 1 | -9.381 | -8.031 | -6.12 | -3.837 | -5.755 | -5.884 |
Operating Margin | -121.38% | -140.09% | -77.85% | -46.46% | -70% | -97.03% |
Earnings before Tax (EBT) 1 | -9.434 | -8.05 | -7.029 | -3.861 | -5.833 | -6.157 |
Net income 1 | -9.434 | -8.05 | -7.029 | -3.861 | -5.833 | -6.157 |
Net margin | -122.07% | -140.41% | -89.42% | -46.75% | -70.96% | -101.52% |
EPS 2 | -0.2074 | -0.1743 | -0.1405 | -0.0675 | -0.1020 | -0.1077 |
Free Cash Flow 1 | 11.43 | -4.046 | -5.653 | -3.123 | -6.254 | -2.552 |
FCF margin | 147.92% | -70.57% | -71.91% | -37.81% | -76.07% | -42.09% |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 4/29/19 | 4/23/20 | 4/20/21 | 5/4/22 | 5/10/23 | 6/5/24 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | - | - | - | 1.95 | 4.36 |
Net Cash position 1 | 8.96 | 2.51 | 5.55 | 0.96 | - | - |
Leverage (Debt/EBITDA) | - | - | - | - | -0.3678 x | -0.7799 x |
Free Cash Flow 1 | 11.4 | -4.05 | -5.65 | -3.12 | -6.25 | -2.55 |
ROE (net income / shareholders' equity) | -51.8% | -87.1% | -92.8% | -50.2% | -104% | -171% |
ROA (Net income/ Total Assets) | -28.4% | -45% | -37.1% | -22.3% | -38% | -36.8% |
Assets 1 | 33.17 | 17.88 | 18.95 | 17.28 | 15.33 | 16.72 |
Book Value Per Share 2 | 0.2800 | 0.1200 | 0.1900 | 0.1000 | 0.0900 | 0.0300 |
Cash Flow per Share 2 | 0.2000 | 0.0500 | 0.1500 | 0.0200 | 0.0100 | 0 |
Capex 1 | 0.37 | 0.32 | 0.54 | 0.12 | - | - |
Capex / Sales | 4.78% | 5.51% | 6.92% | 1.46% | - | - |
Announcement Date | 4/29/19 | 4/23/20 | 4/20/21 | 5/4/22 | 5/10/23 | 6/5/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-34.29% | 1.25M | |
+1.61% | 206B | |
+3.30% | 177B | |
+31.46% | 157B | |
+31.88% | 112B | |
+1.60% | 64.63B | |
+21.17% | 55.63B | |
-1.61% | 47.57B | |
-9.01% | 36.87B | |
+0.23% | 35.18B |
- Stock Market
- Equities
- ALTE Stock
- Financials Alteco Medical AB